Top Markets
Coin of the day
Medivir AB (publ) Medivir AB (publ)

Medivir AB (publ)

MVIR-B
Rangering i aksjer #29651
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Aksjekurs
$0.68377137
Sist synkronisert: 2023-05-23
Markedsverdi
$20.23M
Endring (1 dag)
-0.60%
Endring (1 år)
0.00%
Land
SE
Handel Medivir AB (publ) (MVIR-B)

Kategori

EPS for Medivir AB (publ) (MVIR-B)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Medivir AB (publ) er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Medivir AB (publ) fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter